EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus

Eyepoint Pharma (EYPT) announced an update on their ongoing clinical study.

The COMO phase 3 study from EyePoint Pharmaceuticals, Inc. tests a new eye drug called EYP-1901 in people with diabetic macular edema. The official goal is to compare vision outcomes versus aflibercept, a standard eye injection, and the results could shift how long‑acting eye treatments are viewed in this large and growing disease.

The trial compares two injected drugs given into the eye. EYP-1901 is a tyrosine kinase inhibitor designed for longer disease control, while aflibercept is an established anti-VEGF therapy often used on a frequent dosing schedule.

The study is interventional and randomized, so patients are assigned by chance to one of two groups. It uses a parallel design with both patients and doctors masked, so neither side knows which treatment is given, and the main aim is to see which drug works better for treating eye swelling from diabetes.

The trial was first submitted on Feb. 27, 2026, marking the formal start of the phase 3 program in this setting. The most recent update was posted on Mar. 13, 2026, which confirms the trial plans are current and the study is still in the recruiting stage.

For investors, this update keeps the long-acting retina story alive for EyePoint Pharma (EYPT), as success could support premium pricing and recurring revenue in a large diabetic eye market. It also adds pressure on incumbents like Regeneron’s Eylea and other anti-VEGF players to defend share if a less frequent dosing option proves competitive.

The study remains active and updated, and further details are available on the ClinicalTrials.gov portal.

To learn more about EYPT’s potential, visit the Eyepoint Pharma drug pipeline page.